BioMarin Completes Acquisition of Inozyme Pharma to Enhance Enzyme Therapies BioMarin Pharmaceutical has finalized its acquisition of Inozyme Pharma for $270 million, boosting its enzyme therapy portfolio significantly.

BioMarin Completes Acquisition of Inozyme Pharma to Enhance Enzyme Therapies #United_States #San_Rafael #BioMarin #Inozyme #ENPP1_Deficiency